Christine Mikail Cvijic, serving as both President and Chief Financial Officer of Neurogene Inc., has executed a divestment of company equity in early July 2026. The transactions involved the sale of 4,800 shares of Neurogene common stock, generating a total proceeds value of $173,375. These sales were carried out through two distinct transactions on July 6 and July 7, 2026. The execution of these sales was governed by a Rule 10b5-1 trading plan that Ms. Cvijic established on August 18, 2025. The shares disposed of during this period were previously held in joint ownership with her spouse, David Cvijic.
On July 6, the initial transaction involved the sale of 600 shares at a weighted average price of $36.021 per share. The specific prices for these individual transactions ranged between $36.00 and $36.035. The subsequent day, July 7, saw the sale of an additional 4,200 shares at a weighted average price of $36.134 per share, with individual transaction prices ranging from $36.00 to $36.455. These transactions occurred as Neurogene shares were trading near their 52-week high of $37.27. The stock has experienced a significant 97% surge over the preceding six months. Market data indicates the stock is currently trading at a valuation that exceeds its calculated Fair Value, with additional analytical insights available for subscribers.
Following the completion of these reported sales, Ms. Cvijic's direct holding of Neurogene common stock stands at 84,040 shares. This retained position is composed of several tranches of restricted stock units. This includes 10,635 restricted stock units granted on March 13, 2024, with a vesting date of March 13, 2027. Additionally, she holds 13,533 restricted stock units granted on March 26, 2025, which vest annually in equal installments on March 26, 2027, and March 26, 2028. Furthermore, 22,000 restricted stock units granted on February 20, 2026, are scheduled to vest annually in equal installments on February 20, 2027, February 20, 2028, and February 20, 2029. Upon the completion of the sales reported in this Form 4 filing, Ms. Cvijic no longer maintains any joint shareholdings with her spouse.
The executive sales coincide with broader corporate activity at Neurogene. The company recently announced the pricing of a public offering that includes 3.5 million shares of common stock priced at $30 per share, alongside pre-funded warrants priced at $29.999999 per warrant. The company projects gross proceeds of approximately $125 million from this offering, prior to the deduction of underwriting discounts and other expenses. This capital raise follows a positive analyst action from Leerink, which raised its price target for Neurogene shares to $77 from $70, while maintaining an Outperform rating. Leerink cited positive Phase 1/2 clinical trial data for NGN-401 in Rett syndrome and an increased probability of success estimate from 60% to 70% as key drivers for the adjustment.
Market attention also extends to peer Taysha Gene Therapies, which received a reiteration of its Market Outperform rating and an $11 price target from Citizens. This rating was supported by progress in the TSHA-102 program, with pivotal data and regulatory feedback anticipated by the first half of 2027. Early results from this program have demonstrated improvements in communication and grasping abilities, which are critical metrics for quality of life in this therapeutic area.